First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology

Axitinib, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, will be used in combination first-line therapies against metastatic renal cell carcinoma (mRCC), but its effects as a first-line monotherapy are unclear. Thus, we aimed to elucidate pretreatment clinical factors that...

Descripción completa

Detalles Bibliográficos
Autores principales: Numakura, Kazuyuki, Kobayashi, Mizuki, Muto, Yumina, Sekine, Yuya, Takahashi, Makoto, Kashima, Soki, Yamamoto, Ryohei, Koizumi, Atsushi, Nara, Taketoshi, Saito, Mitsuru, Narita, Shintaro, Nanjyo, Hiroshi, Habuchi, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675987/
https://www.ncbi.nlm.nih.gov/pubmed/33208816
http://dx.doi.org/10.1038/s41598-020-77135-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675987/
https://www.ncbi.nlm.nih.gov/pubmed/33208816
http://dx.doi.org/10.1038/s41598-020-77135-6

Ejemplares similares